Why the CEO Sells 31,000 Shares Worth of AXT Stock
When a company's CEO sells 31,000 shares worth roughly $1.41 million, it sparks questions for investors. This guide e...
This intro covers scenarios where a price-weighted index may be appropriate and how it contrasts with alternative indexing methods.
22,504 articlesWhen a company's CEO sells 31,000 shares worth roughly $1.41 million, it sparks questions for investors. This guide e...
A senior insider at Septerna sold nearly 12,000 shares in a single move, raising questions for investors. This articl...
Biotech investors chase game-changing tech, but CRISPR Therapeutics carries real regulatory milestones and execution ...
Biote's Q1 2026 earnings call reveals critical insights into revenue growth, margins, and a promising pipeline. This ...
A New York-based issuer sells rated notes backed by a pool of bitcoin-backed consumer loans, signaling a milestone fo...
As Liquidia releases its Q4 2025 results, investors crave clarity on revenue, burn rate, and milestones. This article...
When a biotech firm nears a major FDA decision, every insider transaction can feel like a tell. This article dives in...
Barings BDC (BBDC) fans the flames of income investing with a steady cash-flow model. As barings (bbdc) 2025 earnings...
As biotech investors digest Recursion's latest quarterly results, this Deep Dive breaks down what recursion (rxrx) 20...
As Abeona prepares to report 2025 results, investors need a clear framework to interpret the numbers. This guide brea...
When TOI releases earnings, investors watch more than headline numbers. This guide breaks down TOI earnings, what dri...
As 2026 unfolds, investors are watching novavax (nvax) 2026 earnings for clarity on demand, pipeline milestones, and ...